Release
28.11.2018
VALBIOTIS recognized for its IPO at the 2018 INVESTOR AWARDS
Download
Release
12.11.2018
VALBIOTIS announces expansion of application for VALEDIA to include NASH prevention
Download
Release
06.11.2018
VALBIOTIS confirms the publication of the results from international Phase IIA clinical study evaluating VALEDIA® for the risk reduction of type 2 diabetes, by mid-2019
Download
Release
30.10.2018
VALBIOTIS signs scientific partnership with CarMeN, biomedical research laboratory in the field of metabolic diseases
Download
Release
17.10.2018
VALBIOTIS confirms its interest in the study of the intestinal microbiota
Download
Release
08.10.2018
Appointment of Murielle CAZAUBIEL as Head of Development and Medical Affairs
Download
Release
05.10.2018
Strengthening of the liquidity contract (in French)
Download
Release
03.10.2018
VALEDIA®: Key data supporting the submission of a health claim
Download
Release
02.10.2018
Successful capital increase by private placement of € 2.3M (in French)
Download
